Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 396 results for "erbitux"

Merck KGaA Rebif sales hold up despite MS pills
Pharma Times

Merck KGaA Falls After Uninspiring Forecast for 2014 Earnings

March 6 (Bloomberg) -- Merck KGaA fell the most in more than five weeks after the maker of the Erbitux cancer drug disappointed some investors with its 2014 profit forecast. Earnings before interest, taxes, depreciation and amortization excluding ... Washington Post, 1 month ago

4 images for erbitux

TopNews United States, 3 months ago
EuroInvestor, 3 months ago
ABC News 4 Charleston, 3 months ago
Jutia Group, 4 months ago

Antibodies in Oncology Drug Pipeline Update 2014

The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of ...
 MarketResearch.com3 weeks ago

Merck KGaA looks to Erbitux, Gonal-f to drive expansion in emerging markets: report

Belen Garijo, CEO of Merck KGaA's Serono unit, said the company is looking to expand in emerging markets by boosting investment in its existing medicines for cancer and fertility, Bloomberg reported Friday. "Our aspiration is to become a significant ...
 FirstWord Pharma1 month ago

ERBITUX® RECEIVES POSITIVE FUNDING DECISION FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN ENGLAND

Merck Serono, Feltham, 28th February 2014 The Cancer Drugs Fund (CDF) has announced that Erbitux (cetuximab) can be used in the first line setting in combination with oxaliplatin-based chemotherapy FOLFOX4, FOLFOX6 or OxMdG for patients with ...
 PharmiWeb1 month ago Merck Erbitux received approval for insurance reimbursement  Korea IT Times1 month ago Merck Serono's Erbitux to be funded by CDF in England for mCRC  Pharma Letter1 month ago
Daily Finance

Top 10 Financial Scandals of All Time

Timothy A. Clary/AFP/ A Bernie Madoff Halloween mask. Putting together any type of Top 10 list is a dicey business. Once you get past the usual subjects, the criteria for the rest of the candidates is a matter of personal opinion. So for my list of ...
 Daily Finance2 days ago

Korea's public healthcare expands coverage of expensive anti-...

With the introduction of an innovative risk-sharing scheme, South Korea's public healthcare will now provide insurance coverage to four critical illnesses, including Erbitux Injection used for the treatment of metastatic colorectal or rectal cancer, ...
 Enterprise Innovation5 days ago

Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018

Research and Markets (http://www.researchandmarkets.com/research/8rhkdb/biosimilars) has announced the addition of the "" report to their offering. The global market is estimated to reach $2.0 billion by 2018 at a CAGR of more than 20% between 2013 ...
 Individual.com6 days ago Research and Markets: Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018  Pharmacy Choice6 days ago RESEARCH AND MARKETS : Global Biosimilars (Recombinant Non-Glycosylated & Recombinant Glycosylated Proteins & Recombinant Peptides) Market 2013-2018  4 Traders6 days ago Global Monoclonal Antibodies Market in Colorectal Cancer 2013-2019  PredictWallStreet1 week ago
[x]  
Jutia Group

Company Update (NYSE:BMY): Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

[Business Wire] Bristol-Myers Squibb Company announced today the submission of a new drug application on April 4, 2014 to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as ...
 Jutia Group6 days ago Tocagen Names Jamey Skillings, M.D., Chief Medical Officer  HispanicBusiness.com2 weeks ago Company Update (NYSE:BMY): In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1  Jutia Group3 weeks ago Tocagen Inc. Names Chief Medical Officer  BioSpace3 weeks ago
[x]  
Pharma Times

France moving ahead with biosimilar substitution

New legislation in France would allow retail pharmacists there to become the first in Europe to be able to supply patients with biosimilar versions of the biologic drug indicated on the prescription. The new rule, contained within Article 47 of this ...
 Pharma Times6 days ago France moving ahead with biosmilar substitution  Pharma Times1 week ago

Halozyme Therapeutics announces management changes

Halozyme Therapeutics, Inc., a biopharmaceutical company, has appointed Sunil Joshi as vice president and global product team lead, or GPTL, for PEGPH20 and oncology; and Stephen Daly as vice president for Hylenex sales and marketing. Mr Joshi most ...
 Individual.com1 week ago Halozyme Therapeutics, Inc. (HALO) Announces Appointment Of Oncology Product Team Leader And Other Executive Transitions  FierceBiotech2 weeks ago Halozyme Announces Appointment Of Oncology Product Team Leader And Other Executive Transitions  OSIX News2 weeks ago Halozyme Therapeutics, Inc. Announces Appointment Of Oncology Product Team Leader And Other Executive Transitions  BioSpace2 weeks ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - erbitux
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less